TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5ML

INJECTION, SUSPENSION

**4.2. Posology and method of administration** Posology Standard schedule for routine immunization: Administer 0.5 ml at 0 and 6 months. Schedule for individuals at increased risk of invasive meningococcal disease: Administer 2 doses of 0.5 ml at least 1 month apart, followed by a third dose at least 4 months after the second dose. **Booster Dose** A booster dose should be considered following either dosing regimen for individuals at continued risk of invasive meningococcal disease (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Pediatric Population** Safety and efficacy of Trumenba in children below the age of 10 years of age have not been established. **Elderly** Trumenba has not been studied in adults older than 65 years of age. Method of administration For intramuscular injection only. The preferred site for injection is the deltoid muscle of the upper arm. Separate injection sites and different syringes must be used if more than one vaccine is administered at the same time. There are no data available on the interchangeability of Trumenba with other meningococcal serogroup B vaccines to complete the vaccination series.